MaxCyte

MaxCyte is the global leader in electroporation technology, the pre-eminent technology supporting non-viral cell and gene therapies, such as gene editing therapies

MaxCyte

MaxCyte is the global leader in electroporation technology, the pre-eminent technology supporting non-viral cell and gene therapies, such as gene editing therapies

  • Electroporation technology to pharma and biotech for cell therapy development as well as for drug discovery
  • Electroporation is a leading non-viral method of introducing genetic material to a cell
  • Attractive and highly scalable business model of licensing the technology and devices for an annual fee, repeat consumables, development milestone payments and royalties on end-market sales of any products using their tech

Key facts

  1. Sales $26m
  2. Employees c.65
  3. Industry Life Sciences & Healthcare
  4. Headquarters North America
  5. Geographic Footprint Europe, North America
  6. Website www.maxcyte.com
  7. Investment Date February 2021
  8. Fund VIP III Cortex

Investment Facts

MaxCyte

MaxCyte is the global leader in electroporation technology, the pre-eminent technology supporting non-viral cell and gene therapies, such as gene editing therapies

Key facts

  1. Sales $26m
  2. Employees c.65
  3. Industry Life Sciences & Healthcare
  4. Headquarters North America
  5. Geographic Footprint Europe, North America
  6. Website www.maxcyte.com
  7. Investment Date February 2021
  8. Fund VIP III Cortex
  • Electroporation technology to pharma and biotech for cell therapy development as well as for drug discovery
  • Electroporation is a leading non-viral method of introducing genetic material to a cell
  • Attractive and highly scalable business model of licensing the technology and devices for an annual fee, repeat consumables, development milestone payments and royalties on end-market sales of any products using their tech

Back